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Summary
Background Epidermolysis bullosa acquisita (EBA) is a complex autoimmune bul-
lous disease disease with variable clinical presentations and multiple possible
diagnostic tests, making an international consensus on the diagnosis of EBA
essential.
Objectives To obtain an international consensus on the clinical and diagnostic crite-
ria for EBA.
Methods The International Bullous Diseases Group (IBDG) met three times to
discuss the clinical and diagnostic criteria for EBA. For the final voting exer-
cise, 22 experts from 14 different countries voted on 50 different items.
When > 30% disagreed with a proposal, a discussion was held and re-voting
carried out.
Results In total, 48 of 50 proposals achieved consensus after discussion. This
included nine diagnostic criteria, which are summarized in a flow chart. The IBDG
was unable to determine one procedure that would be applicable worldwide. A
limitation of the study is that differential diagnosis of bullous systemic lupus
erythematosus has not been addressed.
Conclusions This first international consensus conference established generally
agreed-upon clinical and laboratory criteria defining the clinical classification of
and diagnostic testing for EBA. Holding these voting exercises in person with the
possibility of discussion prior to voting has advantages in reaching consensus
over Delphi exercises with remote voting.
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What’s already known about this topic?
• Currently, there is a lack of consensus on the diagnosis of epidermolysis bullosa
acquisita (EBA).
What does this study add?
• These recommendations, which have been developed by international experts, pro-
vide appropriate pathways for EBA diagnosis: the algorithms may be used to distin-
guish EBA from other blistering diseases, which affect the epithelial basement
membrane zone.
The International Bullous Diseases Group (IBDG) was formed
in 2005 following a research meeting at the National Institutes
of Health for experts in blistering diseases to work towards a
consensus for the development and validation of definitions
and outcome measures in autoimmune bullous diseases
(AIBDs).1 The IBDG focused its efforts initially on pemphigus,
with consensus definitions, development and validation of the
Pemphigus Disease Area Index and the Autoimmune Bullous
Skin Intensity Score.1,2 Subsequently, the IBDG published con-
sensus definitions for bullous pemphigoid (BP) and proposed
the BP Disease Area Index severity tool,3 and then consensus
definitions for mucous membrane (MM) pemphigoid (MMP)
and the MMP Disease Area Index.4 The current project relates
to international consensus definitions on diagnostic criteria for
epidermolysis bullosa acquisita (EBA).
Two cases of an adult-onset, acquired blistering disease that
was reminiscent of patients with hereditary dystrophic epider-
molysis bullosa (EB) were reported in 1895 by Elliott.5 A land-
mark paper on the subject was published in 1971 by Roenigk
et al., who described three new cases of EBA, reviewed the world
literature and proposed the first diagnostic criteria for EBA.6
These criteria were soon modified by the advent of immunofluo-
rescence (IF) and the finding that all patients with EBA had IgG
and sometimes C3 deposits in their dermoepidermal junction
(DEJ) and that by immunoelectron microscopy (IEM), these DEJ
immune deposits were clearly in a different location than
immune deposits observed in BP.7–10 The IgG autoantibodies
(autoAbs) accounting for these DEJ immune deposits were found
to be autoAbs directed against a 290-kDa protein called type VII
collagen (Col7), the major component of anchoring fibrils (AFs)
in the DEJ.11,12 Since these initial observations, the diagnostic
testing for EBA has undergone significant refinement.13–15
Methods
The IBDG met three times during 2015: at the annual meet-
ings of the American Academy of Dermatology in San Fran-
cisco (21 experts from 11 countries); the European Society of
Dermatological Research in Rotterdam (11 experts from six
countries); and the European Academy of Dermatology and
Venereology (EADV) in Copenhagen (22 experts from 14
countries). Initial presentations and discussions took place at
the first two meetings. After further revisions and discussions
at the third meeting, consensus voting took place on the defi-
nitions and diagnostic techniques. We defined ‘consensus’
according to Harmonize Outcome Measures for Eczema by
having less than one-third of the key opinion leaders disagree-
ing on a given diagnostic criterion.16,17 Fifty proposals
(Table S1; see Supporting Information) were put forward for
discussion and voting related to the diagnostic processes
involved in EBA. For each proposal, participants could ‘agree’,
be ‘undecided’ or ‘disagree’. Tables summarizing the literature
(Tables S2–S6; see Supporting Information) and examples of
cases of EBA (Appendix S2; see Supporting Information) were
presented for discussion.
Results
Altogether, 38 experts in EBA from 15 countries took part in
this consensus, although not all were able to attend all three
international meetings held in San Francisco, Rotterdam and
Copenhagen. The actual results of the voting questions
(Table S7; see Supporting Information) and the reported
anonymized results in the final version of the approved word-
ing or procedures were from 22 blistering disease experts
from 14 different countries (Fig. S1; see Supporting Informa-
tion). Although not all members of the IBDG were present at
the final voting meeting, all co-authors were in agreement
with the EBA diagnostic criteria detailed herein.
Definition and clinical variants of epidermolysis bullosa
acquisita
EBA is defined as a subepithelial AIBD in which patients have
tissue-bound autoAbs targeted against Col7 within AFs of the
basement membrane zone (BMZ) of the DEJ or chorioepithe-
lial junction (CEJ) in stratified squamous epithelia.
Several forms of EBA exist, with two major types, termed:
(i) the classical/mechanobullous form; and (ii) the nonclassi-
cal/nonmechanobullous forms, first described by Gammon
et al. in 1982.18 The latter includes forms that may clinically
resemble BP, MMP, Brunsting-Perry pemphigoid and linear
IgA bullous dermatosis.6,18–35 Table 1 and Figure 1 summa-
rize the descriptions and definitions of these four phenotypes.
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The frequency of these subtypes varies in different countries,
with the classical type being the most common in European
reports and the BP-like form more common in Asia
(Table S2).36–39 It should be recognized that overlapping clin-
ical presentations may also occur (proposal 09, cases 1–5 in
Appendix S2). Overall, because EBA can appear clinically, his-
tologically and immunologically similar to BP,18,20–24 when
the initial diagnostic consideration of the dermatologist is BP,
EBA should also be considered. Furthermore, if certain clinical
clues are somewhat atypical for BP (e.g. lesions that heal with
scarring and the formation of milia, head and neck involve-
ment, mucosal involvement, disease onset before 70 years of
age),40 the diagnostic possibility that the patient has EBA,
rather than BP, rises considerably. Finally, it is important to
classify cases of MM-predominant EBA (MM-EBA) because the
severity of mucosal involvement dictates more aggressive,
multidisciplinary management.
There has been confusion in the literature as to which
forms constitute an ‘inflammatory’ form of EBA.13,20,22,23,36–
39 The IBDG members agreed that the BP-like form is inflam-
matory but that both MM-EBA and IgA-EBA may also be
inflammatory. However, Brunsting-Perry-like EBA is usually a
noninflammatory form of EBA.
Laboratory testing for epidermolysis bullosa acquisita
The IBDG reached agreement on the following proposal: rou-
tine histopathology, direct IF (DIF) microscopy and indirect IF
(IIF) – which are widely available laboratory tests – allow a
diagnosis of subepithelial AIBD but are not able to distinguish
EBA from another subepidermal AIBD. Routine histopathology
on a biopsy obtained from lesional skin or MM of a patient with
EBA shows (i) subepidermal or subepithelial cleavage; (ii) great
variability in the amount or type of inflammatory infiltrate; and
(iii) milia cysts and fibrosis in older lesions. Routine DIF micro-
scopy of perilesional skin or MM shows (i) linear immune
deposits along the BMZ of the DEJ or CEJ, and (ii) no labelling
of dermal blood vessels. The profile of immune deposits
includes IgG and C3 but occasionally IgA or IgM (Table S3, case
report 5; see Supporting Information).41–43 Routine IIF micro-
scopy on monkey, rat or rabbit oesophagus or human skin can
detect anti-BMZ autoAbs, but it is often at a low titre.
Currently, a diagnosis of EBA should be confirmed by at
least one of the following tests, which are only performed in
academic centres and are not widely available to the average
dermatologist worldwide:13,15,35 (i) among tests requiring
skin or MM biopsies – electron microscopy (EM) and direct
IEM,44 serration pattern analysis by DIF41,45,46 and fluorescent
overlay antigen mapping (FOAM);47–49 and (ii) among sero-
logical tests for the detection of circulating autoAbs to
Col7 – enzyme-linked immunosorbent assay (ELISA), IIF on
BIOCHIPTMwith noncollagenous 1 (NC1) Col7-transfected
human cells,50 immunoblotting (IB), IIF on skin deficient in
Col751,52 and/or indirect IEM.44 Obviously, all these serologi-
cal tests require that the patient with EBA has autoAbs to Col7
circulating in their blood and it must be kept in mind that
anti-Col7 autoAbs are also present in bullous systemic lupus
erythematosus (BSLE).53
Alternative laboratory tests when none of these tests is avail-
able include DIF and IIF on salt-split skin (SSS),54 but they
will not absolutely confirm the diagnosis of EBA.55,56
Standard transmission electron microscopy and
immunoelectron microscopy
In patients with EBA, standard transmission EM shows an elec-
tron-dense band immediately below the lamina densa (LD) in
the AF zone. Another EM finding suggestive of EBA is that the
cleavage occurs below the LD, which remains attached to the
roof of the blister. A paucity of AFs also supports a diagnosis
of EBA.44
Table 1 Definitions of clinical forms of epidermolysis bullosa
acquisita (EBA)
Classical/mechanobullous
One subtype only, characterized by:6
• trauma-induced lesions (skin fragility)a
• bullous/vesicular lesions or erosions
• encompassed by noninflamed or scarred skin
• scarringa and milia formationa
• preferably located in trauma-prone sites and the extensor
skin surface (dorsal hands,a elbows,a knees,a Achilles ten-
don, feeta)
• possible nail dystrophya
• possible scarring alopecia
Nonclassical/nonmechanobullous
BP-like EBA, defined as an eruption:18,20–24
• with features characteristic of BP (pruritus, tense bullae
on erythematous or urticarial skin, involvement of trunk
and folds)
• usually mixed with atypical lesions for a BP (skin fragi-
lity, bullae on normal skin, milia, involvement of face or
extensor area of the limbs)
MM-EBA, defined as a disease that predominantly affects MM
lined by squamous epithelium, i.e. MM of:20–27
• mouth
• pharynx
• oesophagus
• epiglottis
• conjunctiva
• genitalia
• anus
• respiratory tract (in malpighian metaplasia)
Brunsting-Perry-type EBA, defined as a chronic recurrent
blistering dermatosis confined to the head and neck28–32
IgA-EBA, defined as a disease that presents with linear IgA
deposits in the BMZ that can be observed by direct IF:20,33,34
• it may resemble LABD
• it may be more aggressive with mucosal scarring
BP, bullous pemphigoid; MM, mucous membranes; BMZ, basal
membrane zone; IF, immunofluorescence; LABD, linear IgA bul-
lous dermatosis. aCriteria of Roenigk.
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(e) (f) (g)
(a) (d)
(c)
(b)
(h) (i) (j)
(k) (l)
(m)
(n)(o)
(p)
(r)
(q)
Fig 1. Clinical subtypes of epidermolysis bullosa acquisita (EBA). (a–g) Classical/mechanobullous form of EBA: trauma-induced lesions are usually
located on extensor skin surfaces, i.e. (a, b) back of the hands, (c) feet, (d) heel, (e) elbows and (f) knees. (b, d) Bullous/vesicular lesions or
erosions are surrounded by noninflamed or scarred skin. Lesions heal with (e, f) scarring and (a, b, f) milia formation. (c) Nail dystrophy and
(g) scarring alopecia are possible. (h–j) Bullous pemphigoid (BP)-like form of EBA: tense bullae on (h) erythematous or (i, j) urticarial skin
suggestive of BP, in atypical locations for BP at extensor areas of the limbs. (k–p) Mucous membrane (MM)-EBA: all the MM lined by squamous
epithelium may be involved in (k) buccal MM (particularly the tongue), (l) anus and (m) oesophagus, leading to strictures and (n) gastrostomy,
(o) conjunctival scarring and (p) tracheal stenosis. (q) IgA-EBA with bullous eruption in a ‘string of pearls’. (r) Brunsting-Perry-type EBA with
recurrent blistering dermatosis confined to the head for 10 years. Images (c), (m) and (o) are reproduced from Figures 611(b), 611(c) and
611(d), and image (h) is reproduced from Fig. 402(a) in Prost-Squarcioni C and Caux F. Management of epidermolysis bullosa acquisita. In:
Blistering Disease: Clinical Features, Pathogenesis, Treatment (Murrell D, ed.). New York: Springer, 2015, with the permission of Springer. Image (g) is
reproduced from Supplementary Figure 1(a) in Zumelzu C, Le Roux-Villet C, Loiseau P et al. Black patients of African descent and HLA-
DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita. J Invest Dermatol 2011; 131:2386–93, with the permission of the Journal of
Investigative Dermatology. Image (p) courtesy of Professor Michel Brauner.
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Direct IEM on perilesional skin shows in vivo bound immune
deposits that are very thick and located in the AF zone, and a
cleavage under immune deposits, if EBA is present (Fig. 2).44
The IBDG agreed on the limitations of direct IEM (proposal
29). Sixteen members of the consensus group attending the
EADV round of voting had EM available at their site, but only
about half of the group had experience in using EM and only
seven were currently using IEM.
Serration pattern analysis
DIF microscopy of a perilesional skin biopsy can distinguish
EBA from other subepithelial AIBD by showing a ‘u-serrated’
linear pattern of immunoglobulin deposits along the BMZ in
EBA and BSLE, and an ‘n-serrated’ pattern of immunoglobu-
lin deposits in BP, antilaminin 332 MMP and anti-p200/
laminin c1 pemphigoid (Fig. 3).41,45,46,55,56 No agreement
was obtained on limitations of the serration pattern analysis
(proposal 26). Indeed, it can be performed with routine DIF
microscopy (new, unpublished data on the exact require-
ments can be read in Supplementary Data S2 of
Appendix S2). However, to date, this test is not widely avail-
able and so far only the teams in Groningen and L€ubeck
have been able to master the technique (proposal 26bis).
Fluorescent overlay antigen mapping analysis
In EBA, FOAM, using routine IF microscopy with either an
image analysis system or laser scanning confocal
microscopy,47–49 shows in vivo bound immune deposits below
the basal keratinocyte membrane, lamina lucida and LD com-
ponents (Fig. 4).
Enzyme-linked immunosorbent assay
Commercially available ELISAs using recombinant NC1/non-
collagenous 2 (NC2) Col7,57–60 or NC1 Col7,50 are widely
available. Sensitivities vary depending on the selection criteria.
It is very high (79–967%) on preselected positive sera by IIF
on SSS, with floor labelling (Table S4; see Supporting Infor-
mation). The sensitivity of ELISA to NC1/NC2 is lower (30–
54%) in studies on unselected EBA sera.39,61
An ELISA using full-length Col7 is more sensitive than an
ELISA using NC1/NC2 Col7 but is not commercially available
(Table S5; see Supporting Information).39,42,62,63
ELISAs for Col7 are not highly specific as they may be posi-
tive in patients with Crohn disease or ulcerative colitis without
cutaneous manifestations of EBA,64 atypical AIBD65 and
patients with recessive dystrophic EB (RDEB) (Tables S5 and
S6).39,63,66,67 Of note, the presence of circulating autoAbs
against BP180, laminin 332 and the p200/laminin c1 chain
(detected by IB or ELISA), which may occur as a result of the
epitope spreading phenomenon, does not rule out a diagnosis
of EBA (supplementary cases 2 and 4 in Appendix S2).37,68–75
Novel technique: indirect immunofluorescence using
noncollagenous 1 type VII collagen-transfected cells
Patient serum autoAbs could label NC1 Col7-transfected cells
on a special slide, a so-called BIOCHIPTM method (Fig. 5). This
test is now commercially available and could be used as a sub-
stitute for the ELISA outlined above. It is a sensitive, specific
and rapid assay for testing preselected positive sera by IIF on
SSS with floor labelling.50 Like serological testing by ELISA, its
sensitivity is lower in studies on unselected EBA sera.39
(a)
(b)
(c)
Fig 2. Immunoelectron microscopy (IEM) in
epidermolysis bullosa acquisita. (a) Direct IEM
using the pre-embedding immunoperoxidase
technique. Thick immune deposits are
observed in the anchoring fibril zone below
the lamina densa (LD) and split (asterisk)
under them. (b, c) Indirect IEM using (b)
pre-embedding immunoperoxidase and (c)
the immunogold technique. Immune deposits
(arrows) decorate the ends of anchoring
fibrils. Images (a), (b) and (c) are reproduced
from Figures 1910(b), 1912(a) and 1912
(b) in Prost-Squarcioni C. Electron
microscopy and immunoelectron microscopy.
In: Blistering Disease: Clinical Features, Pathogenesis,
Treatment (Murrell D, ed.). New York:
Springer, 2015, with the permission of
Springer.
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Immunoblotting
IB is a serological technique performed on extracts of tissues
or cells or recombinant Col7 proteins (Fig. 6).13,15,35 IB is
effective for diagnosing EBA by detecting autoAbs in patient
sera that label the Col7 a-chain. IB can substitute for the
(a)
(b)
Fig 3. Serration pattern analysis by direct immunofluorescence. The
u-serrated pattern is characterized by closed arches at the bottom
appearing like ‘growing grass’, whereas the n-serrated pattern shows
closed arches at the top. (a) Direct immunofluorescence (DIF) of
epidermolysis bullosa acquisita skin showing linear IgG deposition
along the epidermal BMZ in a u-serrated pattern (9 400). (b) DIF of
bullous pemphigoid skin showing linear IgG deposition along the
epidermal basement membrane zone in an n-serrated pattern
(9 400). Images courtesy of Dr Gilles Diercks. [Colour figure can be
viewed at wileyonlinelibrary.com]
(a)
(b)
(c)
(d)
Fig 4. Fluorescence overlay antigen mapping (FOAM) in skin
biopsies. In epidermolysis bullosa acquisita (EBA), in vivo bound
immune deposits are below the a6b4 integrin of the basal
keratinocyte membrane and below the components of the lamina
lucida and the lamina densa (laminin 332 and type IV collagen). (a)
In a patient with EBA, in vivo bound IgG (green) is below type IV
collagen (red). (b) In a patient with a bullous pemphigoid, in vivo
bound IgG (green) is above laminin 332 (red). (c) In a patient with
mucous membrane pemphigoid (MMP), in vivo bound IgG (green) is
below or co-localized (yellow) with laminin 332 (red). (d) In a
patient with MMP, in vivo bound IgG (green) is above or co-localized
(yellow) with type IV collagen (red). Images courtesy of Dr Katarzyna
Wozdniak.
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commercially available ELISA. The IBDG agreed on the limita-
tions of IB (proposal 33).
Indirect immunofluorescence on type VII collagen-deficient
human skin and indirect immunoelectron microscopy
A definitive diagnosis of EBA can be demonstrated by IIF
when presumptive EBA sera label the DEJ of normal human
skin but do not label skin from generalized severe RDEB with
no Col7 (Fig. 7).51,52 Obviously, this is not offered in com-
mercial laboratories and is limited by access to skin specimens
from patients with this exceedingly rare disease.
A definitive diagnosis of EBA can also be demonstrated
when presumptive EBA sera label AFs by indirect IEM
(Fig. 2).44
Direct and indirect immunofluorescence microscopy on
salt-split skin
DIF and IIF on SSS are alternative laboratory tests that only
give a probable diagnosis of EBA. DIF is performed after split-
ting the skin biopsy of the patient using NaCl 1 mol L1
(Supplementary Data S3 in Appendix S2).54,76 It is not possi-
ble with MM biopsies. IIF may be performed on either normal
human SSS using a similar procedure,19,77–79 or monkey SSS,
which is commercially available. Immune deposits in patients
with EBA remain on the dermal floor of the separation,
whereas BP immune deposits remain with the epidermal roof
(a)
(b) (c)
Fig 5. Indirect immunofluorescence microscopy with noncollagenous 1 type VII collagen (NC1 Col7)-expressing human cells by BIOCHIPTM
technology. Patient serum autoantibodies could label molecularly engineered epidermal cells that express human NC1 Col7 on a special slide. (a)
On a standard-sized slide, there are five incubation fields each with two different BIOCHIPs: one with human embryonic kidney (HEK)293 cells
transfected with pTriEx-1, which serve as negative control, and one with human HEK293 cells transfected with NC1 Col7. (b) Autoantibodies in
the serum of a patient with epidermolysis bullosa acquisita labelled NC1 Col7-expressing HEK293 cells (right) but not non-NC1 Col7-expressing
cells (left). (c) No reactivity of either NC1 Col7-expressing or non-NC1-Col7-expressing cells is seen with normal human serum. Images courtesy
of Dr Aucouturier, Paris.
Fig 6. Immunoblotting in epidermolysis bullosa acquisita (EBA). By
immunoblotting with dermal extract, EBA serum recognized a band
at 290 kDa, which is the alpha chain of type VII collagen (Col7),
different from laminin c1/p200 protein. A second band at
145 kDa, which is the amino terminal noncollagenous 1 domain of
the alpha chain of Col7, could be seen. NHS, normal human
serum.
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(Fig. 8). However, this dermal labelling is not specific to
EBA. It is also seen in antilaminin 332 MMP and anti
1-p200/ laminin c1 pemphigoid (Fig. 4). Additional tests
are necessary to exclude reactivity against these molecules
and finally diagnose EBA. Overall, IIF on SSS is more sensi-
tive than IIF on monkey or rat oesophagus or unsplit
human skin for detecting anti-BMZ autoAbs.77,79
Lastly, the IBDG updated consensus criteria for EBA diagno-
sis (2015) include combinations of the following tests: (1) a
bullous disorder within the defined clinical spectrum; (2)
histopathology revealing a subepidermal or subepithelial blis-
ter; (3) a positive DIF microscopy of perilesional skin or MM
with linear IgG, C3, IgA and/or IgM deposits within the
epithelial BMZ; (4) detection of circulating autoAbs against
Col7 by IB, ELISA and/or IIF microscopy on Col7-expressing
human cells; (5) labelling AFs by indirect IEM or negative IIF
microscopy on Col7-deficient skin; (6) a ‘u-serration’ pattern
by DIF microscopy; (7) direct IEM of perilesional skin demon-
strating immune deposits within AFs zone  the lower LD;
(8) in vivo bound immune deposits below type IV collagen by
FOAM; (9) alternatively to items (4)–(8), dermal labelling by
DIF and/or IIF on SSS.
The IBDG did reach agreement that the ideal scenario is for
a patient with putative EBA disease (criterium 1) to exhibit a
subepidermal bulla by histology (criterium 2 optional), a
positive DIF microscopy (criterium 3) and an ELISA (or
another serological test) showing that the patient’s serum
autoAbs target Col7 [criterium (4) or (5)]. In this scenario,
a highly probable diagnosis of EBA is made and no further
tests need to be done for confirmation. Unlike this ideal sce-
nario for the diagnosis of EBA, the problem that often arises
is when a patient with EBA lacks circulating autoAbs and
therefore IIF, SSS IIF and ELISA are negative.39,61 Then the
diagnosis of EBA could be considered definitive if criteria
(1) and (3) and at least one of criteria (6)–(8) are present
(a)
(b)
Fig 7. Indirect immunofluorescence (IIF) microscopy on type VII
collagen (Col7)-deficient skin vs. normal skin. (a) IIF microscopy with
epidermolysis bullosa acquisita (EBA) serum on Col7-containing
normal human skin showing positive IgG binding along the epidermal
basement membrane zone (BMZ) (9 400). (b) IIF microscopy with
EBA serum on Col7 knockout skin from a patient with severe
generalized recessive dystrophic epidermolysis bullosa showing
negative IgG binding along the epidermal BMZ (9 400). Images
courtesy of Dr Hendri Pas, Groningen, the Netherlands.
(a)
(b)
(c)
(d)Fig 8. Indirect immunofluorescence
microscopy on salt-split skin. An artificial
cleavage is induced by NaCl 1 mol L1 in (a,
b) monkey skin (counterstained with Evans
blue; images Courtesy of Dr Aucouturier,
Paris) or (c, d) normal human skin. (a, c)
Labelling of the floor of the cleavage by the
serum of a patient with EBA. (b, d) Labelling
of the roof of the cleavage by the serum of a
patient with bullous pemphigoid.
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[criterium (2) is optional]. Lastly, if tests (6)–(8) cannot be
done, a diagnosis of EBA is possible if items criteria (1), (3)
and (9) are present; then diagnosis has to be confirmed by
exclusion of autoimmunity against laminin 332 or the
p200/laminin c1 chain. The consensus conference was not
able to determine one procedure that would be applicable
worldwide. There was an animated discussion about what
should be considered routine (Proposal 18). Which test(s)
that the practitioner chooses will likely be determined by the
clinical presentation of the patient (classical/mechanobullous
type or not), the geography of the practitioner and which
test is most logistically accessible. Figure 9 summarizes the
different diagnostic investigative pathways.
In conclusion, this consensus of the criteria for the diagno-
sis of EBA provides a general framework for establishing a
diagnosis of EBA and takes into account the clinical presenta-
tion and available laboratory testing. These criteria should help
prevent clinicians from misdiagnosing other AIBDs and miss-
ing the diagnosis of EBA. They will also be useful for future
studies designed to define the natural history and therapeutic
outcomes of EBA.
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Fig 9. Flow chart for diagnosis of epidermolysis bullosa acquisita (EBA). Type VII collagen (Col7)-specific enzyme-linked immunosorbent assays
(ELISAs) include noncollagenous (NC)1, NC1/NC2 or full-length Col7 ELISAs. BIOCHIPTM technology uses NC1 Col7-transfected human
embryonic kidney (HEK)293 cells as a substrate for indirect immunofluorescence (IIF) microscopy (IIFT test). Col7-deficient skin is obtained from
patients with generalized severe recessive dystrophic epidermolysis bullosa. DIF, direct immunofluorescence; DEJ, dermoepidermal junction; CEJ,
chorioepithelial junction; AIBD, autoimmune blistering disease; autoAb, autoantibody; Col7, type VII collagen; WB, Western blotting; MM,
mucous membranes; IEM, immunoelectron microscopy; FOAM, fluorescence overlay antigen mapping; Col4, type IV collagen; LL, lamina lucida;
LD, lamina densa; BP, bullous pemphigoid; MMP, mucous membrane pemphigoid; SSS, salt-split skin (artificial cleavage obtained by incubation of
normal monkey or human skin with NaCl 1 mol L1). aNC1 ELISA, NC1/NC2 ELISA, NC1 Col7-transfected HEK293 cells and monkey SSS are
commercially available; bnegativity on Col7-deficient skin is significant if IIF microscopy on normal human skin is positive; cinclude WB with
dermal extract or recombinant C-terminus laminin c1 or IIF on laminin 332-deficient skin.
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